{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:19Z","timestamp":1788306559527,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jinf.2021.04.031","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T03:33:27Z","timestamp":1619753607000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination"],"prefix":"10.1016","volume":"83","author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Banzhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Wals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Marlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Bekkat-Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2021.04.031_bib0001","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2021.04.031_bib0002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0003","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.04.031_bib0004","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.04.031_bib0005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/microorganisms8101521","article-title":"Vaccines against meningococcal diseases","volume":"8","author":"Pizza","year":"2020","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.jinf.2021.04.031_bib0006","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0007","unstructured":"European medicines agency. Bexsero. Summary of product characteristics. 2020. [Internet] [cited 2020 Aug 24]. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.jinf.2021.04.031_bib0008","unstructured":"Bexsero. Australian product information. [internet]. [cited 2020 Aug 21].Available from https:\/\/au.gsk.com\/media\/404836\/bexsero_pi_007.pdf"},{"key":"10.1016\/j.jinf.2021.04.031_bib0009","unstructured":"Bexsero Canadian product monograph. 12 June 2020. [Internet] [cited 2020 Aug 24]. Available from https:\/\/ca.gsk.com\/media\/1212390\/bexsero.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0010","unstructured":"Bexsero\u00ae (Meningococcal Group B Vaccine). Prescribing information. [internet] [cited 2020 July 26] Available from http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM431447.pdf. 2018."},{"key":"10.1016\/j.jinf.2021.04.031_bib0011","unstructured":"Trumenba US Prescribing Information 2018. [Internet] [cited 2020 Aug 24]. Available from https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Package-Insert\u2014TRUMENBA.pdf"},{"key":"10.1016\/j.jinf.2021.04.031_bib0012","unstructured":"European medicines agency. Trumenba. Summary of product characteristics. 2020. [Internet] [cited 2020 Aug 24]. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trumenba."},{"key":"10.1016\/j.jinf.2021.04.031_bib0013","unstructured":"Trumenba product information (Australia). 27 August 2018. [Internet] [cited 2020 Aug 24]. Available from https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-meningococcal-group-b-vaccine-180827-pi.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0014","unstructured":"Trumenba product monograph (Canada). 24 May 2019. [Internet] [cited 2020 Aug 24]. Available from https:\/\/www.pfizer.ca\/sites\/default\/files\/201907\/Trumenba_PM_E_220373_24May2019.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0015","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2147\/IDR.S159952","article-title":"Meningococcal group B vaccine for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroup B","volume":"12","author":"Rivero-Calle","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jinf.2021.04.031_bib0016","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jinf.2020.07.034","article-title":"Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence","volume":"81","author":"Borrow","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2021.04.031_bib0017","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0018","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/INF.0000000000001742","article-title":"Adverse events following vaccination with bivalent rLP2086 (Trumenba(R)): an observational, longitudinal study during a college outbreak and a systematic review","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2021.04.031_bib0019","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/07448481.2017.1285772","article-title":"Rapid response to a college outbreak of meningococcal serogroup B disease: nation's first widespread use of bivalent rLP2086 vaccine","volume":"65","author":"Fiorito","year":"2017","journal-title":"J Am Coll Health"},{"key":"10.1016\/j.jinf.2021.04.031_bib0020","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI), 2014. JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK. [Internet]. [cited 2020 Apr 24]. Available from https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0021","unstructured":"Ireland National Immunisation Office. Immunisation Schedule. [Internet]. [cited 2020 Apr 23] Available from https:\/\/www.hse.ie\/eng\/health\/immunisation\/pubinfo\/pcischedule\/immschedule\/."},{"key":"10.1016\/j.jinf.2021.04.031_bib0022","unstructured":"Italy Ministry of Health. Piano Nazionale Prevenzione Vaccinale PNPV 2017-2019. [Internet]. [cited 2020 Apr 23] Available from http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0023","unstructured":"Ministry of Health of The Republic of Lithuania. Official: children in Lithuania will be vaccinated against type B meningococcus [cited 2019 January 23]. Available from https:\/\/sam.lrv.lt\/en\/news\/minister-of-health-aurelijus-veryga-signed-an-order-by-which-vaccines-against-type-b-meningococcus-are-to-be-included-in-the-schedule-for-the-preventive-vaccination-of-children-the-start-of-the-vaccination-is-scheduled-as-of-july-this-year."},{"key":"10.1016\/j.jinf.2021.04.031_bib0024","unstructured":"Government of Malta. National Immunisation Schedule. Updated July 2020. [Internet] [cited 2020 Aug 24]. Available from https:\/\/deputyprimeminister.gov.mt\/en\/phc\/pchyhi\/Pages\/National-Immunisation-Schedule.aspx."},{"key":"10.1016\/j.jinf.2021.04.031_bib0025","unstructured":"World Health Organization. Routine immunization profile. Andorra. 2017. [Internet] [cited 2020 Apr 23]. Available from http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0015\/420504\/AND.pdf?ua=1."},{"key":"10.1016\/j.jinf.2021.04.031_bib0026","unstructured":"Sb\u00edrka Z\u00e1kon\u016f\u010desk\u00e1 Republika. Rozesl\u00e1na dne 27. dubna 2020. [Internet] [cited 2020 Aug 24]. Available from https:\/\/www.epravo.cz\/_dataPublic\/sbirky\/2020\/sb0073-2020.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0027","unstructured":"SA\u00daDE. Gabinete do Secret\u00e1rio de Estado da Sa\u00fadeDespacho n.\u00b0 12434\/2019. [Internet] [cited 2020 Aug 24]. Available from https:\/\/dre.pt\/application\/conteudo\/127608823."},{"key":"10.1016\/j.jinf.2021.04.031_bib0028","first-page":"52","article-title":"[Immunisation schedule of the Spanish Association of Paediatrics: 2020 recommendations]","volume":"92","author":"Alvarez Garcia","year":"2020","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.jinf.2021.04.031_bib0029","unstructured":"Government of South Australia. SA Health. Meningococcal B Immunisation Program. [internet] [cited 2020 Jun 16]. Available from https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/conditions\/immunisation\/immunisation+programs\/meningococcal+b+immunisation+program."},{"key":"10.1016\/j.jinf.2021.04.031_bib0030","unstructured":"Australian Government, Department of Health. Clinical update: National Immunisation Program (NIP) schedule changes from 1 July 2020 \u2013 advice for vaccination providers. 3 June 2020. [internet] [cited 2020 Jun 16]. Available from https:\/\/www.health.gov.au\/news\/clinical-update-national-immunisation-program-nip-schedule-changes-from-1-july-2020-advice-for-vaccination-providers."},{"key":"10.1016\/j.jinf.2021.04.031_bib0031","first-page":"1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2021.04.031_bib0032","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0033","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.04.031_bib0034","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.04.031_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jpids\/piz024","article-title":"US college students are at increased risk for serogroup B meningococcal disease","volume":"9","author":"Marshall","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jinf.2021.04.031_bib0036","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0037","unstructured":"Patel M, Briere E, Duffy J, Miller M, Breakwell L, McNamara L, et\u00a0al. Use of a novel serogroup B meningococcal vaccine in response to two university outbreaks in the US (Abstract O22). IPNC, 2014. [accessed 2017 Oct 2]. http:\/\/neisseria.org\/ipnc\/2014\/IPNC_2014_abstracts.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0038","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jinf.2021.04.031_bib0039","doi-asserted-by":"crossref","first-page":"520","DOI":"10.15585\/mmwr.mm6520a3","article-title":"Notes from the field: Outbreak of serogroup B meningococcal disease at a university - California, 2016","volume":"65","author":"Biswas","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2021.04.031_bib0040","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.jinf.2021.04.031_bib0041","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0042","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0043","unstructured":"South Australian Meningococcal B Expert Working Group. A Meningococcal B Program for South Australia. Public Report 22 June 2018. [cited 2020 Jun 16]. Available from https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/b82a9fb7-061a-48b9-be37-54e88a1907d1\/2018-06+Optimal+Men+B+Program+for+SA+Public+Report+%282%29.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-b82a9fb7-061a-48b9-be37-54e88a1907d1-n5iiiDg."},{"key":"10.1016\/j.jinf.2021.04.031_bib0044","unstructured":"Tozer S, Whiley D, Smith H, Rockett R, Jennison A, Doyle CA, et\u00a0al. Use of the meningococcal antigen typing system to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine. [cited 2021 Mar 02] In: Program and abstracts of the 20th International Pathogenic Neisseria Conference, Manchester, United Kingdom, September 4\u20139, 2016. Available from http:\/\/ipnc2016.org\/IPNC2016AbstractBook.pdf"},{"key":"10.1016\/j.jinf.2021.04.031_bib0045","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.04.031_bib0046","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1636","article-title":"Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0047","unstructured":"Public Health England, 2018. Using paracetamol. [internet] [cited 2020 Apr 23]. Available from https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/483408\/9413-paracetamol-menB-2page-A4-08-web.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0048","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.04.031_bib0049","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/archdischild-2019-318047","article-title":"Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience","volume":"105","author":"Isitt","year":"2020","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jinf.2021.04.031_bib0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12916-016-0642-2","article-title":"Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines","volume":"14","author":"Argante","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.jinf.2021.04.031_bib0051","unstructured":"Argante L, Abbing V, Vadivelu K, Rappuoli R, Medini. D. Effectiveness of a serogroup B meningococcal vaccine (4CMenB) in England: A re-assessment applying computational modelling to real-world evidence. ESPID Vitual meeting 26-29 October 2020."},{"key":"10.1016\/j.jinf.2021.04.031_bib0052","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0053","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3201\/eid2307.170236","article-title":"Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016","volume":"23","author":"Campbell","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0054","article-title":"First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England","author":"Ladhani","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0055","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","article-title":"Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates","volume":"38","author":"Biolchi","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0056","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/vaccines8030469","article-title":"Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018)","volume":"8","author":"Azzari","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jinf.2021.04.031_bib0057","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2021.04.031_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176177","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal","volume":"12","author":"Simoes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2021.04.031_bib0059","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1016\/j.vaccine.2018.10.095","article-title":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada","volume":"36","author":"De Serres","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0060","unstructured":"Agenzia Italiana del Farmaco (AIFA), Rapporto Vaccini 2017, 2018 [internet]. [cited 2020 April 29]. Available from www.aifa.gov.it\/sites\/default\/files\/Rapp_Vaccini_2017_0.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0061","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.28.1700590","article-title":"Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination","volume":"23","author":"Thabuis","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jinf.2021.04.031_bib0062","article-title":"Enhanced passive surveillance of adverse events following immunisation during implementation of a meningococcal B vaccine herd immunity study \u201cB-PART-OF-IT\u201d in senior school students in Australia","author":"Marshall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0063","unstructured":"De Serres G, Gariepy MC, Billard MN, Rouleau I. Initial dose of a multicomponent serogroup B meningococcal vaccine in the Saguenay\u2013 Lac-Saint-Jean Region, Qu\u00e9bec, Canada: an interim safety surveillance report [cited 2018 August 02]. Available from https:\/\/www.inspq.qc.ca\/pdf\/publications\/1902_SerogroupB_Meningococcal_Vaccine.pdf. 2014."},{"key":"10.1016\/j.jinf.2021.04.031_bib0064","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jinf.2021.04.031_bib0065","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2020.05.089","article-title":"The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis","volume":"38","author":"Stowe","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0066","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1016\/j.vaccine.2020.07.009","article-title":"Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia","volume":"38","author":"Marshall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0067","unstructured":"Australian Government. Therapeutic Goods Administration. Bexsero meningococcal B vaccine. Final update - monitoring finds no new or unexpected safety issues 22 March 2016. [internet]. [cited 2020 April 29]. Available from https:\/\/www.tga.gov.au\/monitoring-communication\/bexsero-meningococcal-b-vaccine."},{"key":"10.1016\/j.jinf.2021.04.031_bib0068","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero(\u00ae): Prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0069","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.17.17-00468","article-title":"Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016","volume":"23","author":"Mentzer","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jinf.2021.04.031_bib0070","unstructured":"Institut National de Sant\u00e9 Publique de Qu\u00e9bec. Enqu\u00eate \u00e9pid\u00e9miologique sur l'association entre le vaccin Bexsero et le syndrome n\u00e9phrotique, 2018. [cited 2020 Jun 18]. Available from https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/2354_enquete_association_vaccin_bexsero_syndrome_nephrotique.pdf."},{"key":"10.1016\/j.jinf.2021.04.031_bib0071","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1016\/j.vaccine.2020.05.055","article-title":"Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: an ecological study","volume":"38","author":"Andrews","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.04.031_bib0072","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1186\/s12889-020-09487-7","article-title":"Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017","volume":"20","author":"Pivette","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jinf.2021.04.031_bib0073","article-title":"Killing 2 cocci with 1 vaccine: unleashing the full potential of an adolescent meningococcal B immunization program","author":"Ladhani","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0074","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/cix091","article-title":"Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015-2016","volume":"64","author":"Soeters","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0075","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/jix446","article-title":"Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015-2016","volume":"216","author":"McNamara","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0076","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jinf.2021.04.031_bib0077","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jinf.2021.04.031_bib0078","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1073\/pnas.93.20.11109","article-title":"Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities","volume":"93","author":"Tinsley","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jinf.2021.04.031_bib0079","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0080","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.04.031_bib0081","first-page":"S46","article-title":"Case-control study to evaluate the effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea, New York City and Philadelphia, 2016\u20132018","volume":"47","author":"Abara","year":"2020","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.jinf.2021.04.031_bib0082","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:33:05Z","timestamp":1759008785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445321002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0163445321002188"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2021.04.031","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2021.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}